home
Author : adminDate : 2016-05-10 14:21

Apatinib — new third-line option for refractory gastric or GEJ cancer

Author : Toru Aoyama & Takaki Yoshikawa


Source : NATURE-REVIEWS


Abstract

Apatinib significantly improves both the progression-free survival (PFS) and overall survival in patients with advanced-stage gastric cancer who are

refractory to two or more lines of chemotherapy. In the context of previous phase III trials of angiogenesis inhibitors for this disease, we discuss the role

of apatinib, and the advantages and limitations of VEGFR‑2 blockade in the advanced disease setting.


Click for details